000306670 001__ 306670
000306670 005__ 20260108125130.0
000306670 0247_ $$2doi$$a10.1016/j.wneu.2025.124684
000306670 0247_ $$2pmid$$apmid:41318094
000306670 0247_ $$2ISSN$$a1878-8750
000306670 0247_ $$2ISSN$$a1878-8769
000306670 037__ $$aDKFZ-2025-02663
000306670 041__ $$aEnglish
000306670 082__ $$a610
000306670 1001_ $$aSantacroce, Antonio$$b0
000306670 245__ $$aGyroscopic Radiosurgery - Clinical Experience and Prospective Analysis of over 500 Treated Tumors.
000306670 260__ $$aAmsterdam$$bElsevier$$c2026
000306670 3367_ $$2DRIVER$$aarticle
000306670 3367_ $$2DataCite$$aOutput Types/Journal article
000306670 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767873060_3506152
000306670 3367_ $$2BibTeX$$aARTICLE
000306670 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000306670 3367_ $$00$$2EndNote$$aJournal Article
000306670 500__ $$aVolume 205, January 2026, 124684
000306670 520__ $$aStereotactic radiosurgery (SRS) plays a significant role in the treatment of various benign and malignant tumors of the central nervous system. Recently, the first self-shielding treatment platform for gyroscopic radiosurgery (GRS) was introduced. Herein, we report our experience with GRS treatment of the first 541 tumors in a prospective setting.This study enrolled patients who underwent GRS for intracranial tumors. Patient, treatment, and outcome data were prospectively collected and analyzed. Only patients with at least one imaging and clinical follow-up were included in this analysis. Volumetric assessments and major toxicity are presented.A total of 491 patients were treated between 2021 and 2024. Of those, 382 patients harboring 541 tumors underwent at least one imaging and clinical follow-up. The majority of tumor entities treated were vestibular schwannomas (196), brain metastases (188), and meningiomas (113). The median prescription dose for brain metastases was 20 Gy. For meningiomas and vestibular schwannomas, the median prescription doses were 15 and 13 Gy, respectively. Analysis of dosimetric performance showed that GRS treatments are highly conformal, achieving steep dose gradients. The median imaging follow-up was 10.6 months. Volumetry of the treated targets demonstrated an early treatment effect, with either tumor volume reduction or stability for most tumors.The early results of this prospective study, which enrolls patients undergoing GRS, show the efficacy and safety of the new self-shielding treatment platform. Due to the limited follow-up of this analysis, future studies including long-term outcome data are needed.
000306670 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000306670 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000306670 650_7 $$2Other$$aZAP-X
000306670 650_7 $$2Other$$abrain metastasis
000306670 650_7 $$2Other$$agyroscopic radiosurgery
000306670 650_7 $$2Other$$ameningioma
000306670 650_7 $$2Other$$aradiosurgery
000306670 650_7 $$2Other$$astereotactic radiosurgery
000306670 650_7 $$2Other$$avestibular schwannoma
000306670 7001_ $$aMuacevic, Alexander$$b1
000306670 7001_ $$aKohlhase, Nadja$$b2
000306670 7001_ $$aEftimova, Dochka$$b3
000306670 7001_ $$aHofmann, Theresa$$b4
000306670 7001_ $$aSammer, Matthias$$b5
000306670 7001_ $$aGraser, Annabel$$b6
000306670 7001_ $$aKufeld, Markus$$b7
000306670 7001_ $$aFürweger, Christoph$$b8
000306670 7001_ $$0P:(DE-HGF)0$$aEhret, Felix$$b9
000306670 773__ $$0PERI:(DE-600)2530041-6$$a10.1016/j.wneu.2025.124684$$gp. 124684 -$$p124684$$tWorld neurosurgery$$v205$$x1878-8750$$y2026
000306670 909CO $$ooai:inrepo02.dkfz.de:306670$$pVDB
000306670 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000306670 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000306670 9141_ $$y2025
000306670 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bWORLD NEUROSURG : 2022$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-12
000306670 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-12
000306670 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK Koordinierungsstelle Berlin$$x0
000306670 980__ $$ajournal
000306670 980__ $$aVDB
000306670 980__ $$aI:(DE-He78)BE01-20160331
000306670 980__ $$aUNRESTRICTED